key: cord-0960626-vfi8ourj
authors: Wang, Lindsey; Berger, Nathan A.; Xu, Rong
title: Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
date: 2021-11-23
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.37575
sha: a7271ac0013d630f889be4e7ef7fa56cd8e41a16
doc_id: 960626
cord_uid: vfi8ourj

This cohort study assesses the risk of breakthrough SARS-CoV-2 infection and hospitalization among fully vaccinated patients with multiple myeloma.

This study used the cloud based TriNetX Analytics network platform that allows access to deidentified patient electronic health records from 63 health care organizations in the United States.

The study population comprised 473,244 patients fulfilled the following inclusion criteria: had recent medical encounter(s) with healthcare organizations since December 1, 2020, had TriNetX Analytics is a federated cloud-based network providing web-based real-time secure access to patient EHRs from hospitals, primary care and specialty treatment providers of diverse geographic locations, age groups, race/ethnic groups, and income levels. Though the EHR data are de-identified, end-users can use web-based TriNetX Analytics built-in functions (e.g., propensity score matching, risk, time trend analysis, Kaplan-Meier survival) that work on underlying patient-level EHR data for cohort selection and matching, analyzing incidence and prevalence of events in a cohort, comparing characteristics and outcomes between matched cohorts, among others. Multiple studies have used TriNetX to study risk, disparity, sequelae, temporal trends, clinical characteristics, and outcomes of COVID-19. 

All the statistical analyses were performed within TriNetX Analytics Platform using its built-in functions unless it was specified otherwise. (1) We tested whether fully vaccinated MM patients had higher risk for breakthrough infections than matched non-cancer patients. MM cohort and non-cancer cohort were propensity-score matched for (a) demographics (age, gender, race/ethnicity), (b) adverse socioeconomic determinants of health (SDOHs) related to education, unemployment, occupational hazard exposure, housing and economic circumstances, among others, (c) transplant procedures, (d) comorbidities including hypertension, heart disease, cerebrovascular diseases, obesity, type 2 diabetes, chronic lung diseases, liver diseases, chronic kidney diseases, smoking, alcohol drinking, substance use disorders that are known risk factors for COVID-19 infection or severe outcomes from COVID-19 infection [33] [34] [35] [36] [37] [38] [39] , and (e) vaccine types (Pfizer, Moderna, J&J). TriNetX built-in propensity-score matching function was used (1:1 matching using a nearest neighbor greedy matching algorithm with a caliper of 0.25 times the standard deviation) for controlling for the list of variates described above. The outcome was COVID-19 infections followed starting 14 days after patients received the second dose of Pfizer-BioNTech or Moderna vaccine or single dose J.&J. vaccine up to the end of time window (October 8, 2021) . Kaplan-Meier analysis was used to estimate the probability of breakthrough infections from 14 days after full vaccination up to October 8, 2021. Comparisons between cohorts were made using a log-rank test and the hazard ratio (HR) was used to describe the relative risk of breakthrough infections based on comparison of time to event rates. The proportional hazard assumption was tested using the generalized Schoenfeld approach.

(2) We tested whether fully vaccinated patients with breakthrough infections had different risk for hospitalization compared with a matched cohort without

For the breakthrough cohort, Kaplan-Meier analysis was used to estimate the probability of hospitalization starting from the day of infection up to October 8, 2021. For the non-breakthrough cohort, Kaplan-Meier analysis was done to estimate the probability of hospitalization starting